Bristol-Myers Squibb Compnay

Zheng Lin

Paul E Morin

Martin J Corbett

Alexander T Kozhich

Murli Krishna

Steven P Piccoli

Mohan Srinivasan

Arvind Rajpal

Stanley Richard Krystek, Jr

Yong Zhang

Gregory D Vite

Chetana Rao-Naik

Alla Pritsker

Virginie Lafont

A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.

Prodruggable antibodies, prodrugs thereof, and methods of use and making

Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in immunogenicity assay development to detect such anti-drug antibodies. Such antibodies exhibit preferential binding based on the size of PEG with molecular weight ranging from 350 daltons to 40 kD. Anti-PEG antibodies of the invention are engineered to comprise human Fc regions to enable non-bridging immunoassay formats.

Method of using human FC-bearing IGG antibodies to polyethylene glycol

Antibodies to polyethylene glycol

Provided herein are methods for refolding proteins. The methods involve covalently modifying a denatured protein with a nonproteinaceous polymer and then renaturing the modified protein.

Methods for protein refolding

Growing community of inventors

North Wales, PA, United States of America

Zheng Lin